Congratulations to Catherine Cai on matching to New York Presbyterian Hospital-Weill Cornell Med Ctr-NY! Catherine says, "I am simply elated to be moving to one of the best cities in the world to train at one of the best hospitals in the country. The MD/PhD journey is a long and often lonely one, but it makes Match Day that much sweeter for us. I am grateful for my family here in the MD/PhD program and for the support I received from the School of Medicine." Best of luck for a bright fulfilling career.
M.D./Ph.D. candidate Nick Steinauer successfully defended his dissertation "Role of the Hematopoietic Corepressor CBFA2T3 in Acute Myeloid Leukemia" in April, under the mentorship of Jinsong Zhang. He is excited to begin his M3 year of medical school in June.
Stephen Grote, Ph.D. successfully defended his dissertation, "Neuronostatin: a Novel Factor in Glucose Counterregulation" on April 15 via Zoom call. He will be returning to medical school as an M3 in June.
Daniel successfully defended his dissertation: "Neutrophil-Derived Bioactive Lipids in Sepsis" in April. He loved working in the Ford lab and will miss being a part of it, but he is excited to start the next chapter in his training and rejoin medical school in June.
Congratulations to Kevin Bockerstett, Ph.D., successfully defending his dissertation "The Role of Inflammation in Gastric Carcinogenesis." via a Zoom call during the COVID-19 crisis. Kevin will rejoin medical students as a M3 student to finish his training as a medical student.
Saint Louis University School of Medicine Virtual Match Day 2020. Congratulations to Ananthi Rajamoorthi, M.D., Ph.D., on matching to her first choice at New York Presbyterian Children's Hospital/Columbia University Pediatric Physician- Scientist Program. Best wishes for an exciting future.
Nick Steinauer, M.D./Ph.D. student in Dr. Zhang's lab, recently published a paper in Blood Advances. Congratulations. Steinauer, N., Guo, C., Huang, C., Wong, M., Tu, Y., Freter, C. E., & Zhang, J. (2019). Myeloid translocation gene CBFA2T3 directs a relapse gene program and determines patient-specific outcomes in AML. Blood Advances, 3(9), 1379 LP – 1393.